a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announced that its immunogenicity testing technology is being presented by Allergan at the 10th Workshop on Recent Issues in Bioanalysis in Orlando, Florida (“10th WRIB”), on April 19, 2016.
The case study presentation will be given by Dr. Swati Gupta, PhD, Director of Immunology for Allergan. The title of the talk is “SQI Ig_plex Dual-Layer Multiplexing Capabilities in Immunogenicity Assays” and will provide novel case studies from products that were developed on SQI’s multiplexing platform used in immunogenicity testing. The presentation will provide comparison of SQI tests to traditional bridging assays using a competitor’s “electrochemiluminescent” technology. The presentation will provide data emphasizing SQI’s improved drug tolerance, sensitivity, the ability to run all targets in one test and how to use the technology to profile for safety and efficacy of therapeutics.
"SQI is excited to see its immunogenicity products showcased again this year at the WRIB conference. The repeated validation and market exposure gained from the presentation and case study by Allergan is important," said Andrew Morris, CEO of SQI Diagnostics. "We believe that our technology provides industry-leading performance and benefits for the testing of multiple anti-drug antibody targets in a single test; significantly improved work-flow and reduced labor costs; and, it enables drug developers to align their processes with the emerging regulatory guidelines surrounding immunogenicity testing worldwide.”
Immunogenicity testing is just one of a series of assay types that are being run on SQI’s automated multiplexing technology.
SQI representatives will be at the presentation to answers questions and will be available throughout the conference and we encourage you to come to booth 31 for more information about our custom assay development services, products and fully automated systems.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.
Sales and Marketing Contact
Vice President, Global Commercial Operations
Investor Relations Contact
Chief Executive Officer
416.674.9500 ext. 229
Vice President of Finance
416.674.9500 ext. 299
This news release contains certain forward-looking statements, including, without limitation, statements containing the words “will”, “expects”, “intends” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to agreements and future agreements to sell our products, the failure to obtain necessary regulatory approvals, general economic and market segment conditions, and international risk and currency exchange, the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business, the acceleration of our revenue ramp, general economic and market segment conditions, competitor activity, technology changes and regulatory approvals. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.